Post-shingles neuralgia by any definition is painful, but is it PHN?

Mayo Clinic Proceedings

Volumn 86, Issue 12, 2011, Pages 1141-1142

  Yawn, Barbara P ^a  

^a OLMSTED MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VARICELLA ZOSTER VACCINE;

ALGORITHM; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DISEASE DURATION; EDITORIAL; HERPES ZOSTER; HUMAN; PAIN; POSTHERPETIC NEURALGIA; PREVALENCE;

EID: 83155193104     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/mcp.2011.0724     Document Type: Editorial

References (11)

1. Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recom Rep. 2008;57(RR-5):1-30. http://www.cdc.gov/mmwr /preview/mmwrhtml/ rr5705a1.htm. Accessed November 7, 2011.
2. US Department of Health and Human Services; US Food and Drug Administration (FDA). FDA approves Zostavax vaccine to prevent shingles in individuals 50 to 59 years of age. http://www.fda.gov/newsevents /newsroom/pressannouncements/ucm248390.htm. Accessed November 7, 2011.
3. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005; 352(22):2271-2284.
4. Klompas M, Kulldorff M, Vilk Y, Bialek SR, Harpaz R. Herpes zoster and postherpetic neuralgia surveillance using structured electronic data. Mayo Clin Proc. 2011;86(12):1146-1153.
5. Tseng HF, Smith N, Harpaz R, Bialek SR, Sy LS, Jacobsen SJ. Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. JAMA. 2011;305(2):160-166.
6. Insinga RP, Itzler RF, Pellissier JM, Saddier P, Nikas AA. The incidence of herpes zoster in a United States administrative database. J Gen Intern Med. 2005;20(8):748-753. (Pubitemid 41141008)
7. Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007;82(11):1341-1349. (Pubitemid 350060129)
8. Yawn BP, Wollan PC, St. Sauver J. Comparing shingles incidence and complication rates from medical record review and administrative database estimates: how close are they [published online ahead of print September 13, 2011]? Am J Epidemiol. doi:10.1093/aje/kwr206 Yawn 2011 AJE.
9. Kost RG, Straus S. Postherpetic neuralgia: prevalence, pathogenesis, treatment, and prevention. N Engl J Med. 1996;335(1):32-42. (Pubitemid 26230812)
10. Pellissier JM, Brisson M, Levin MJ. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine. 2007;25(49):8326-8337. (Pubitemid 350087379)
11. Rothberg MB, Virapongse A, Smith KJ. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Clin Infect Dis. 2007;44(10):1280-1288. (Pubitemid 46717289)